Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: April 24, 2025
Reporting Period: Events occurring on April 24, 2025, with certain agreements effective April 1, 2025.
Business Context: The Company is an emerging growth company incorporated in Texas, trading on the Nasdaq Capital Market. This filing details the entry into material definitive agreements regarding the expansion into a smokeless product vertical and executive compensation adjustments.
Key Financial Metrics and Agreements
This filing does not contain standard financial statements (revenue, profit, cash flow, or debt levels). Instead, it discloses specific transactional commitments:
- Intellectual Property Acquisition: Purchase of IP, contracts, and know-how related to oral pouches for nutritional and wellness products from Smokeless Technology Corp.
- Consideration for IP: 1,600,000 shares of restricted common stock and a 10% royalty on gross worldwide sales of associated products.
- Royalty Terms: Royalty payments commence on the first anniversary of the effective date (April 23, 2026) and are payable annually in perpetuity.
- Consulting Arrangement: Agreement with Strategem Solutions Inc. for services related to product innovation and commercialization.
- Consulting Consideration: 120,000 shares of common stock (vesting 10,000/month) and $12,500 monthly cash payments (accrued until a $1.5 million capital raise is completed).
- Executive Compensation: Amendment to CEO Jacob D. Cohen's agreement increasing base salary to $420,000/year, office allowance to $10,000/month, and car allowance to $5,000/month. Additionally, Cohen receives 3,192,906 shares of subsidiary (Mango & Peaches Corp.) stock.
Material Changes Versus Prior Period
The filing does not provide comparative financial data against prior periods. Material changes include:
- Strategic Expansion: Entry into a new business vertical involving smokeless oral pouches via the acquisition of IP from Smokeless Technology Corp.
- Capital Structure: Issuance of 1,600,000 shares for IP and 120,000 shares for consulting services, representing new equity dilution.
- Liability Obligations: Creation of a perpetual 10% royalty obligation on future sales of specific product lines starting in 2026.
- Executive Control: Following the issuance of subsidiary stock, CEO Jacob Cohen will own 49% of the outstanding common stock of Mango & Peaches Corp. and hold voting control via Series A Super Majority Voting Preferred Stock.
Guidance, Outlook, and Risks
Outlook and Strategy: Management is actively developing a pouch division and smokeless product vertical, leveraging the acquired IP and the expertise of Tim Corkum (Director of Smokeless) as President of a new subsidiary.
Risks and Contingencies:
- Liquidity Dependency: Cash payments for the consulting agreement ($12,500/month) are contingent upon the Company completing a successful raise of at least $1.5 million in debt or equity. Until then, these payments accrue.
- Future Obligations: The 10% royalty on gross sales represents a significant future cash outflow contingent on the commercial success of the new product line.
- Unregistered Securities: The shares issued for the IP purchase and consulting agreement were exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D, subject to transfer restrictions.
Investor Verification Checklist
- Verify the exact number of shares issued for the IP purchase (1,600,000) and consulting (120,000) and their impact on total outstanding shares.
- Confirm the status of the $1.5 million capital raise required to fund accrued consulting fees.
- Review the definition of "Mango Purchased IP Products" to understand the scope of the 10% royalty obligation.
- Assess the voting control implications of Jacob Cohen's ownership in the Mango & Peaches Corp. subsidiary.
- Examine the full text of the IP Purchase Agreement (Exhibit 10.1) for specific details on the patents and trademarks acquired.